In April 2026, the Trump administration released a presidential action outlining plans to adjust imports of pharmaceuticals and their ingredients into the United States. The policy is designed to incentivize pharmaceutical companies to shift production to the United States while also giving the government greater leverage in pricing negotiations. It targets high-cost branded medications and key imported inputs, though some lower-cost generics and essential medicines may be exempt to avoid widespread disruption. Overall, the proposal reflects a more aggressive trade-based approach to reshaping the pharmaceutical supply chain and strengthening domestic manufacturing capacity. The PHSL May 2026 poll asked readers about their concerns regarding this proposal. The poll results indicate that the leading concern around proposed pharmaceutical tariffs is the impact on patients.

As the Trump administration implements or proposes high tariffs (up to 100%) on imported pharmaceuticals to promote domestic manufacturing, what concerns you most about their potential impact on the pharmacy industry and patient care?

Sharp increases in drug acquisition costs and reimbursement pressures for pharmacies: 20%

Supply chain disruptions and potential shortages of key medications: 10%

Higher out-of-pocket costs for patients, leading to reduced adherence: 40%

Increased financial burden on health plans with higher ingredient costs: 10%

Limited overall impact if companies quickly onshore production or negotiate exemptions: 20%